Background Advantages of the arteriovenous fistula (AVF), including long patency and few
complications, were ascertained more than 2 decades ago and may not apply to the …

Vascular access for haemodialysis is key in renal patients both due to its associated
morbidity and mortality and due to its impact on quality of life. The process, from the creation …

Recognizing the impact of the decision making by the dialysis access surgeon on the
successful placement of autogenous arteriovenous hemodialysis access, the Society for …

Fistulas are the preferred permanent hemodialysis vascular access but a significant obstacle
to increasing their prevalence is the fistula's high “failure to mature”(FTM) rate. This study …

OBJECTIVE: Patency rates for autogenous accesses are presumed to be better than for
polytetrafluoroethylene (PTFE) accesses, although the strength of the supporting evidence is …

Vascular access dysfunction is one of the leading causes of morbidity and mortality among
end‐stage renal disease patients. Vascular access dysfunction exists in all three types of …

The arteriovenous fistula (AVF) was first described and used as a reliable form of
hemodialysis (HD) vascular access (VA) by Brescia et al.(1) in 1966. Improvements in …

Despite all the progress achieved since Scribner first introduced the arteriovenous (AV)
shunt in 1960 and Cimino and Brescia introduced the native AV fistula in 1962, we have …

Purpose To evaluate safety and efficacy of arteriovenous fistulas (AVFs) created with a
thermal resistance anastomosis device. Materials and Methods A prospective single-arm …

PURPOSE: The Dialysis Outcome Quality Initiative (DOQI) guidelines recommend that
arteriovenous fistulas (AVF) be constructed in at least 50% of hemodialysis access …